Companies › Precigen
5 active drug programs in 5 registered trials: 3 Phase 1, 1 Phase 2, 1 Phase 4; Oncology, Infectious disease; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Zopapogene imadenovec p53 gene therapy delivered via adenoviral vector | TP53 | Phase 4 | Recurrent Respiratory Papillomatosis | Dec 2027 |
| PRGN-2009 Oncolytic virus expressing human GM-CSF | – | Phase 2 | Cervical Cancer | Nov 2026 |
| PRGN-3005 UltraCAR-T cells Autologous CAR T cells targeting a protein on tumor cells | – | Phase 1 | Platinum-Resistant Fallopian Tube Carcinoma | Nov 2028 |
| PRGN-2012 Gene therapy for recurrent respiratory papillomatosis | – | Phase 1 | Recurrent Respiratory Papillomatosis | – |
| PRGN-3006 T Cells Anti-CD33 chimeric antigen receptor (CAR) T cell therapy | CD33 | Phase 1 | Acute Myeloid Leukemia | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04724980 | PRGN-2012 | Phase 1 | Recurrent Respiratory Papillomatosis | Infectious disease | Jun 2024 |
| NCT03927261 | PRGN-3006 T Cells | Phase 1 | Acute Myeloid Leukemia | Oncology | Aug 2024 |
| NCT06157151 | PRGN-2009 | Phase 2 | Cervical Cancer | Oncology | Nov 2026 |
| NCT06538480 | Zopapogene imadenovec | Phase 4 | Recurrent Respiratory Papillomatosis | Infectious disease | Dec 2027 |
| NCT03907527 | PRGN-3005 UltraCAR-T cells | Phase 1 | Platinum-Resistant Fallopian Tube Carcinoma | Oncology | Nov 2028 |
Cash and short-term investments of $51m on 2026-09-30; operating cash outflow about $67m a year; runway about 9 months at that burn, to Jul 2027; 1 of 1 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 4 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
GeoVax Bio-Path Holdings PersonGen BioTherapeutics (Suzhou) Hrain Biotechnology Marzieh Ebrahimi
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.